MA52299A - Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer - Google Patents

Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer

Info

Publication number
MA52299A
MA52299A MA052299A MA52299A MA52299A MA 52299 A MA52299 A MA 52299A MA 052299 A MA052299 A MA 052299A MA 52299 A MA52299 A MA 52299A MA 52299 A MA52299 A MA 52299A
Authority
MA
Morocco
Prior art keywords
lif
individuals
cancer
procedures
improving
Prior art date
Application number
MA052299A
Other languages
English (en)
Inventor
Folgueira Judit Anido
Peter Edward Bayliss
Teixidor Ester Bonfill
Patricia Anne Giblin
Robin Matthew Hallett
Ruano Isabel Huber
Ajitha Jeganathan
Jeanne Magram
Garcia Monica Pascual
Rigol Ester Planas
Suarez Joan Seoane
Original Assignee
Fundacio Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron, Medimmune Ltd filed Critical Fundacio Inst Catalana De Recerca I Estudis Avancats
Publication of MA52299A publication Critical patent/MA52299A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052299A 2018-06-18 2019-06-17 Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer MA52299A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382431 2018-06-18
EP19382131 2019-02-22

Publications (1)

Publication Number Publication Date
MA52299A true MA52299A (fr) 2021-04-21

Family

ID=68136437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052299A MA52299A (fr) 2018-06-18 2019-06-17 Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer

Country Status (11)

Country Link
US (1) US20210253691A1 (fr)
EP (1) EP3807315A2 (fr)
JP (1) JP7520727B2 (fr)
KR (1) KR20210024007A (fr)
CN (1) CN112703202A (fr)
AU (1) AU2019291305B2 (fr)
CA (1) CA3103763A1 (fr)
IL (1) IL279484A (fr)
MA (1) MA52299A (fr)
SG (1) SG11202012619WA (fr)
WO (1) WO2019243898A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3555132T1 (sl) * 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (fr) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Anticorps reconnaissant le facteur d'inhibition de la leucémie humaine (LIF) et utilisation d'anticorps anti-LIF pour le traitement de maladies associées à la prolifération de cellules indésirables
EP3173483A1 (fr) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents pour le traitement de maladies associées à une prolifération cellulaire indésirable
EP3490581A4 (fr) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. Compositions neuromodulatrices et méthodes associées de traitement du cancer
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
CN112703202A (zh) 2021-04-23
IL279484A (en) 2021-01-31
JP2021529162A (ja) 2021-10-28
AU2019291305A1 (en) 2021-01-28
AU2019291305B2 (en) 2024-03-21
WO2019243898A8 (fr) 2020-09-24
SG11202012619WA (en) 2021-01-28
KR20210024007A (ko) 2021-03-04
JP7520727B2 (ja) 2024-07-23
CA3103763A1 (fr) 2019-12-26
US20210253691A1 (en) 2021-08-19
WO2019243898A3 (fr) 2020-02-13
EP3807315A2 (fr) 2021-04-21
WO2019243898A2 (fr) 2019-12-26

Similar Documents

Publication Publication Date Title
EP3811971A4 (fr) Anticorps permettant de bloquer l'interaction cd47-sirpa et application associée
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EP3723513A4 (fr) Probiotiques et métabolites de fermentation pour la prévention et le traitement d'états pathologiques chez des animaux
EP2385114A4 (fr) Diagnostic de traitement d'un cancer à l'aide d'un anticorps anti-tm4sf20
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
EP3827837A4 (fr) Composition visant à prévenir et traiter des maladies liées au système immunitaire
EP3849573A4 (fr) Bactériothérapie contre proprionibacterium acnes pour le traitement de l'acné
EP3655531A4 (fr) Séquençage d'acides nucléiques associés à l'isolement exosomal chez des patients atteints de glioblastome multiforme
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
CO2018000414A2 (es) Inmunoconjugados de il22
EP3863673A4 (fr) Traitement avec des compositions d'igg hautement sialylées
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
EP3437646A4 (fr) Préparation orale présentant une exceptionnelle aptitude à l'élution
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
PL3377909T3 (pl) Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3496754A4 (fr) Efficacité d'un conjugué anticorps-médicament anti-hla-dr (hl243-cl2a-sn -38) dans le traitement des cancers hla-dr positifs